Description of Business and Significant Accounting Policies - Additional Information (Detail)		3 Months Ended			6 Months Ended		12 Months Ended
	Mar. 01, 2017	Jun. 30, 2018 USD ($) Distributor	Mar. 31, 2018 USD ($)	Jun. 30, 2017 USD ($)	Jun. 30, 2018 USD ($) Distributor Contract	Jun. 30, 2017 USD ($)	Dec. 31, 2017 USD ($) Distributor Contract	Dec. 31, 2018 USD ($)	Sep. 30, 2018 USD ($)
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Accumulated deficit		$ (2,906,085,000)			$ (2,906,085,000)		$ (2,854,898,000)
Cash and cash equivalents		26,178,000			26,178,000		43,946,000
Principal amount of outstanding borrowings		$ 129,200,000			$ 129,200,000
Stock split of common stock	0.2
Reverse stock split, description					The Company’s board of directors approved a 1-for-5 reverse stock split of the Company’s outstanding common stock. On March 1, 2017, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment of the Company’s Amended and Restated Certificate of Incorporation (the “Charter Amendment”) to effect the 1-for-5 reverse stock split of the Company’s outstanding common stock (the “Reverse Stock Split”) . The Company’s common stock began trading on the Nasdaq Global Market on a split-adjusted basis when the market opened on March 3, 2017. As a result, prior to March 3, 2017, all common stock share amounts included in these condensed consolidated financial statements have been retroactively reduced by a factor of five, and all common stock per share amounts have been increased by a factor of five, with the exception of the Company’s common stock par value.
Net deferred revenue							$ 3,038,000
Number of wholesale distributors | Distributor		3			3		3
Percentage of product shipments to wholesale distributors		89.00%		93.00%	88.00%	93.00%
Revenue - other		$ 3,893,000		$ 2,163,000	$ 7,358,000	$ 5,172,000
Loss on purchase commitments					$ 101,500,000
Loss on purchase commitments, number of new contracts recognized | Contract					0		0
Change in net revenue
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Reduction to net revenue			$ 400,000
Third party logistics
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Net deferred revenue							$ 1,500,000
AFREZZA product sales
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Percentage of estimated products returned		2.46%			2.46%
Revenue - other		$ 3,753,000		1,548,000	$ 7,155,000	2,745,000
Bulk insulin sales and sale of intellectual property
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Revenue - other				$ 600,000		$ 2,300,000
Tranche B Notes
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Senior notes, effective interest rate		8.75%			8.75%
Principal amount of outstanding borrowings		$ 7,000,000			$ 7,000,000
Senior convertible notes due December 31, 2019
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Senior notes, effective interest rate		9.75%			9.75%
Principal amount of outstanding borrowings		$ 32,000,000			$ 32,000,000
Senior convertible notes due December 31, 2019 | Tranche B Notes
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Principal amount of outstanding borrowings		39,000,000			39,000,000		$ 54,407,000
Deerfield | Tranche B Notes
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Principal amount of outstanding borrowings		$ 20,000,000			$ 20,000,000
Deerfield | Senior convertible notes due December 31, 2019
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Senior notes, effective interest rate		9.75%			9.75%
Principal amount of outstanding borrowings		$ 120,000,000			$ 120,000,000
Deerfield | Senior convertible notes due December 31, 2019 | Tranche B Notes
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Available amount of credit facility under covenant restrictions for each quarter end after current fiscal		$ 25,000,000			$ 25,000,000
Senior notes, effective interest rate		8.75%			8.75%
Minimum | AFREZZA product sales
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Sales return right following product expiration in months					6 months
Minimum | Deerfield | Senior convertible notes due December 31, 2019 | Tranche B Notes
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Available amount of credit facility under covenant restrictions		$ 20,000,000	$ 20,000,000		$ 20,000,000
Minimum | Deerfield | Scenario Forecast | Senior convertible notes due December 31, 2019 | Tranche B Notes
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Available amount of credit facility under covenant restrictions								$ 20,000,000	$ 20,000,000
Maximum | AFREZZA product sales
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Sales return right following product expiration in months					12 months